Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016', provides in depth analysis on Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted pipeline therapeutics. The report provides comprehensive information on the Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - The report reviews Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Overview 7 Therapeutics Development 8 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Products under Development by Stage of Development 8 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Products under Development by Therapy Area 9 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Products under Development by Indication 10 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Products under Development by Companies 13 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Companies Involved in Therapeutics Development 20 Daiichi Sankyo Company, Limited 20 Galmed Pharmaceuticals Ltd 21 GlaxoSmithKline Plc 22 Johnson & Johnson 23 Novartis AG 24 Sanofi 25 Thesan Pharmaceuticals, Inc. 26 Xenon Pharmaceuticals Inc. 27 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Drug Profiles 28 Aramchol - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 GSK-1940029 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 SAR-224 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecule to Inhibit SCD1 for Metabolic Disorders - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 TSN-2898 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 XEN-801 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Dormant Projects 41 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Discontinued Products 42 Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Featured News & Press Releases 43 Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China 43 Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial 43 Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease 44 Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study 45 Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne 45 Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease 46 Sep 24, 2015: Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial 47 Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America 47 Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States 48 Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production 49 Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers 49 Nov 13, 2014: Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones 50 Sep 23, 2014: Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 50 Sep 02, 2014: Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events 51 Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 52 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Route of Administration, H2 2016 18 Number of Products by Stage and Molecule Type, H2 2016 19 Pipeline by Daiichi Sankyo Company, Limited, H2 2016 20 Pipeline by Galmed Pharmaceuticals Ltd, H2 2016 21 Pipeline by GlaxoSmithKline Plc, H2 2016 22 Pipeline by Johnson & Johnson, H2 2016 23 Pipeline by Novartis AG, H2 2016 24 Pipeline by Sanofi, H2 2016 25 Pipeline by Thesan Pharmaceuticals, Inc., H2 2016 26 Pipeline by Xenon Pharmaceuticals Inc., H2 2016 27 Dormant Projects, H2 2016 41 Discontinued Products, H2 2016 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
